Voyager Therapeutics, Inc.

Thank you, Life Science Cares Boston, for hosting this event. Robin Swartz and Michelle Quinn Smith were inspired by work across many organizations to alleviate the effects of poverty in Boston. They’ve been among the Voyagers who are proud to support Boston-area organizations as one of your corporate partners!

ICYMI: Here’s the replay of our 4/7 live webcast, Voyager and KOL AD/PD™ 2025 Recap. We’re excited to see data and momentum around tau and to keep advancing our two tau-targeting programs for Alzheimer’s disease patients. https://bit.ly/3EiAhjv

This week at #ADPD2025, Voyager is presenting preclinical data from two of our programs targeting tau for the treatment of Alzheimer’s disease: tau silencing gene therapy VY1706 and anti-tau antibody VY7523. We continue to view tau as the next critical target in Alzheimer’s disease, and we look forward to learning from third-party tau data at ADPD as well. We’ll host a live webcast recapping key conference data on April 7 at 4:30 p.m. ET. View our 3/31 press release: https://bit.ly/43DkGFG

Voyager’s Kumar Dhanasekharan is presenting about successful implementation of large scale manufacturing of novel capsids with complex payloads at this week’s 8th Annual Gene Therapy Development Summit. He’ll also take part in a panel discussion “Navigating the Complex Supply Chain for Gene Therapies.” Learn more about the conference: https://bit.ly/4j0XPbw

Neurocrine Biosciences CEO Kyle W. Gano joined Al Sandrock for a fireside chat at our town hall. Kyle’s remarks about resilience, teamwork and persistence for patients resonated across our values. “Sometimes if you believe in the science you have to execute well, keep your nose to the grindstone and let the data play out.” Thanks for the inspiration, Kyle! https://bit.ly/43GJH2q

📣 Breaking News: Voyager has announced positive topline data from our single ascending dose trial of VY7523, an investigational anti-tau antibody developed to selectively inhibit the spread of pathological tau in Alzheimer’s disease (AD). We’ve also initiated a multiple ascending dose trial of VY7523 in patients with early AD, expected to generate initial tau positron emission tomography imaging data in the second half of 2026. https://bit.ly/43fpcdd

Voyagers are #BetterTogether at events like our Lunar New Year celebration and film screening inspired by Black History Month and the International Day of Women & Girls in Science. Thank you to the Voyagers who planned these gatherings so closely linked to our values. https://bit.ly/4i9XxOZ

We’re excited to introduce Raj Rajagovindan, who has joined Voyager as Vice President of Translational Medicine.   With over 15 years of industry experience, Raj brings extensive expertise in translational and precision medicine approaches to clinical development in Alzheimer’s disease and other neurodegenerative diseases. His work will help to further propel Voyager’s pipeline of neurogenetic medicines as they advance through clinical testing.

Last week, Nobel Prize winner Dr. Phil Sharp joined Voyager CEO Al Sandrock for an inspiring fireside chat at our town hall. Dr. Sharp’s insights from his groundbreaking work on RNA splicing and his pivotal role in shaping the biotech industry left Voyagers awestruck. Here’s one of Dr. Sharp’s many impactful quotes: “The highest calling of what we can do is help others… You’re incredibly privileged to be in a position to take science, discover and innovate. That is a remarkably gratifying activity.” Thank you for joining us, Dr. Sharp!

Attending last month’s Massachusetts Conference for Women in Boston, members of our Women at Voyager Engage ERG heard from inspiring keynote speakers, including Caitlin Clark, Robin Roberts, Gayle King, and Oprah Winfrey, among others.      Our ERG members found the conference’s theme of #PowerInUnity directly resonated with Voyager’s own core value of Better Together: https://bit.ly/4h6ALrk. The meeting provided a unique opportunity to participate in sessions on trusting your inner voice, creating cultures of belonging that transform teams, taking charge of your career, and redefining failure as your gateway to innovation and growth.